DirectCare AI

AI-powered telehealth platform for chronic care management and virtual specialty programs like TRT and GLP-1.

Website: https://www.directcare.ai/

Founders, Backgrounds, and Bench

DirectCare AI is led by solo founder Scott Hozebin, who serves as Chief Executive Officer [Forbes Councils, 2024].

Summary and Signal

DirectCare AI is a telehealth platform combining direct-to-consumer virtual clinics with institutional software for AI-powered remote patient monitoring [Perplexity Sonar Pro Brief]. The company targets two revenue streams: a B2C offering for specialty care programs like GLP-1 weight loss and hormone replacement therapy, and a B2B platform enabling clinics to deploy chronic care programs [DirectCare AI].

Its differentiation rests on positioning between telehealth facilitators and clinical workflow tools, using AI to personalize treatment and automate monitoring tasks [Newswire, March 2025]. The founding team is led by a solo founder whose public profile includes membership in the Forbes Technology Council and concurrent roles as a growth advisor and managing director at other firms [Forbes Councils, 2024].

Data Accuracy: YELLOW -- Core product claims are sourced from company materials and a single review article; founder role is confirmed by Forbes Councils. Funding, traction, and team details lack independent verification.

Company Overview

DirectCare AI is a 2025 entrant in the telehealth and remote patient monitoring space, headquartered in South Florida [DirectCare AI]. The company positions itself as a response to infrastructure gaps in primary care, aiming to modernize clinical workflows with AI automation [LinkedIn, May 2024].

The company is led by solo founder Scott Hozebin [Forbes Councils, 2024]. Hozebin's concurrent roles as a Managing Director at MetaEquity Partners and an advisor at Better Health suggest a background in business development and growth strategy [Forbes Business Development Council, 2025]. Operational milestones include the launch of direct-to-consumer virtual clinics for GLP-1 and TRT, and the promotion of a B2B remote patient monitoring solution [Newswire, March 2025] [DirectCare AI].

Data Accuracy: YELLOW -- Company website and founder profile provide basic details; founding year and solo founder status are consistent across sources.

The Product and the Stack

DirectCare AI's platform serves both individual consumers and healthcare institutions. For patients, the offering is a direct-to-consumer virtual clinic focused on GLP-1 weight loss, testosterone replacement therapy (TRT), hormone replacement therapy (HRT), and hair loss treatments [DirectCare AI]. The patient journey includes an online medical history intake, a consultation with a US-licensed physician, and home delivery of personalized medication [DirectCare AI].

For healthcare providers, the platform is marketed as a turnkey solution to implement Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) programs. The company claims its system enables remote patient enrollment, integrates with connected health devices, and uses AI to help clinical staff track patient vitals [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Product features are described consistently across the company's website and a single third-party review.

The Market They Are Entering

The market for AI-enhanced telehealth and remote patient monitoring is expanding as providers seek scalable ways to manage chronic populations. The US remote patient monitoring market was valued at approximately $1.2 billion in 2023 and is projected to grow at a compound annual rate of over 18% through 2030 [Grand View Research, 2024]. The global GLP-1 agonist market is forecast to exceed $100 billion by 2031 [Research and Markets, 2024].

Metric Value
US Remote Patient Monitoring Market 2023 $1.2B
Projected CAGR 2024-2030 18%
Global GLP-1 Agonist Market 2031 $100B

Data Accuracy: YELLOW -- Market sizing is based on analogous third-party reports for broad categories.

The Competitive Field

DirectCare AI faces distinct rivals in each segment. In the direct-to-consumer men's and women's health clinic space, it competes with venture-backed telehealth providers like Hims & Hers, Ro, and Everly Health. For its institutional RPM and CCM offerings, the competition includes healthcare IT vendors such as Health Recovery Solutions, Vivify Health, and Biofourmis.

Data Accuracy: YELLOW -- Competitor identification is public, but analysis of segment dynamics relies on inferred market structure.

Opportunity

DirectCare AI’s opportunity hinges on capturing a share of the virtual specialty care market by building a dual-channel platform. The company is already operating in the space, with a live platform offering physician-supervised treatment plans and medication delivery [DirectCare AI].

Data Accuracy: YELLOW -- Opportunity analysis is based on company positioning and one third-party review.

Sources

Articles about DirectCare AI

Related companies

Topics

View on Startuply.vc